Colchicine in Patients with Chronic Coronary Disease

• Published in: The New England journal of medicine Vol. 383; no. 19; pp. 1838 - 1847
• Main Authors: Nidorf, Stefan M, Fiolet, Aernoud T.L, Mosterd, Arend, Eikelboom, John W, Schut, Astrid, Opstal, Tjerk S.J, The, Salem H.K, Xu, Xiao-Fang, Ireland, Mark A, Lenderink, Timo, Latchem, Donald, Hoogslag, Pieter, Jerzewski, Anastazia, Nierop, Peter, Whelan, Alan, Hendriks, Randall, Swart, Henk, Schaap, Jeroen, Kuijper, Aaf F.M, van Hessen, Maarten W.J, Saklani, Pradyot, Tan, Isabel, Thompson, Angus G, Morton, Allison, Judkins, Chris, Bax, Willem A, Dirksen, Maurits, Alings, Marco, Hankey, Graeme J, Budgeon, Charley A, Tijssen, Jan G.P, Cornel, Jan H, Thompson, Peter L
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 05.11.2020
• Subjects: Aged; Anti-Inflammatory Agents - adverse effects; Anti-Inflammatory Agents - therapeutic use; Cardiovascular diseases; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - mortality; Cerebral infarction; Chronic Disease; Clinical trials; Colchicine; Colchicine - adverse effects; Colchicine - therapeutic use; Coronary Disease - drug therapy; Death; Design; Double-Blind Method; Drug dosages; Female; Follow-Up Studies; Heart attacks; Heart diseases; Humans; Incidence; Intention to Treat Analysis; Ischemia; Male; Medical imaging; Medical research; Middle Aged; Myocardial infarction; Patients; Proportional Hazards Models; Statistical analysis; Stroke; Netherlands
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2021372

Patients with chronic coronary disease were randomly assigned to receive 0.5 mg of colchicine once daily or matching placebo. The incidence of the composite end point of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization was significantly lower with colchicine than with placebo.